Ricardo Dolmetsch

机构：UniQure (Netherlands)

发表论文 7 篇 · 总被引 287 次 · h-index 4

代表论文

• Evaluating the state of the science for adeno-associated virus integration: An integrated perspective (2022 · Molecular Therapy · 被引 209)
• Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B (2023 · Blood Advances · 被引 58)
• Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up (2022 · Blood · 被引 11)
• Evaluation of One‐Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy (2025 · Haemophilia · 被引 4)
• Durability of Bleeding Protection and Factor IX Activity Levels Are Demonstrated in Individuals with and without Adeno-Associated Virus Serotype 5 Neutralizing Antibodies (Titers <1:700) with Comparable Safety in the Phase 3 HOPE-B Clinical Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B (2022 · Blood · 被引 4)
• Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up (2023 · Hämostaseologie · 被引 1)